Agile Therapeutics, Inc.
AGRX · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $9,702 | $1,251 | $5,779 | $7,080 |
| - Cash | $2,848 | $2,615 | $2,557 | $2,873 |
| + Debt | $289 | $378 | $2,172 | $2,517 |
| Enterprise Value | $7,143 | -$986 | $5,394 | $6,724 |
| Revenue | $5,576 | $5,716 | $3,614 | $6,662 |
| % Growth | -2.4% | 58.2% | -45.8% | – |
| Gross Profit | $4,080 | $4,036 | $1,423 | $4,185 |
| % Margin | 73.2% | 70.6% | 39.4% | 62.8% |
| EBITDA | -$2,746 | $1,572 | -$4,065 | -$360 |
| % Margin | -49.2% | 27.5% | -112.5% | -5.4% |
| Net Income | -$11,872 | $1,284 | -$4,470 | -$799 |
| % Margin | -212.9% | 22.5% | -123.7% | -12% |
| EPS Diluted | -1.73 | 0.28 | -1.51 | -0.27 |
| % Growth | -717.9% | 118.5% | -459.3% | – |
| Operating Cash Flow | $233 | -$2,476 | $172 | $365 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $233 | -$2,476 | $172 | $365 |